Smokers and nonsmokers equally affected by olanzapine-induced weight gain: Metabolic implications

Schizophrenia Research

Volumn 66, Issue 2-3, 2004, Pages 163-167

  Lasser, Robert A ^a   Mao, Lian ^a   Gharabawi, Georges ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Olanzapine; Risperidone; Smoking; Weight gain

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT COURSE THERAPY; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0346786309     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(03)00153-1     Document Type: Conference Paper

References (13)

1. Arcavi L., Jacob P., Hellerstein M., Benowitz N.L. Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumption. Clin. Pharmacol. Ther. 56:1994;55-64.
2. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr. Scand. 100:1999;3-16.
3. Benowitz N.L. Pharmacologic aspects of cigarette smoking and nicotine addiction. N. Engl. J. Med. 319:1988;1318-1330.
4. Benowitz N.L., Jacob P., Yu L. Daily use of smokeless tobacco: systemic effects. Ann. Intern. Med. 111:1989;112-116.
5. Conley R.R., Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 158:2001;765-774.
6. Forchuk C., Norman R., Malla A., Vos A., Martin M.L. Smoking and schizophrenia. J. Psychiatr. Ment. Health Nurs. 4:1997;355-359.
7. George T.P., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am. J. Psychiatry. 157:2000;1835-1842.
8. Hellerstein M.K., Benowitz N.L., Neese R.A., Schwartz J.M., Hoh R., Jacod P., Hsieh J., Faix D. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J. Clin. Invest. 93:1994;265-272.
9. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
10. Melkerson K.I., Hulting A.L., Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry. 61:2000;742-749.
11. Perkins K.A. Metabolic effects of cigarette smoking. J. Appl. Physiol. 72:1992;401-409.
12. Vander Weg M.W., Klesges R.C., Ward K.D. Differences in resting energy expenditure between black and white smokers: implications for postcessation weight gain. Eur. J. Clin. Nutr. 54:2000;895-899.
13. Wonnacott S., Drasdo A., Sanderson E., Rowell P. Presynaptic nicotinic receptors and the modulation of neurotransmitter release. Bock G., Marsh J. The Biology of Nicotine Dependence. 1990;87-102 Wiley, Chichester.